Clinical Trial

NeoTIL in Advanced Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Single center, single arm pilot trial to test the feasibility, safety and efficacy of NeoTIL-ACT combined with low-dose irradiation (LDI) in patients with advanced, recurrent or metastatic solid tumors. The trial is based on lymphodepleting chemotherapy followed by LDI, and then ACT utilizing ex vivo expanded TIL, enriched for tumor antigen specificity (NeoTIL), in combination with high dose Interleukin-2 (IL-2) (optional, depending on patient's tolerance). LDI will be administered once to metastatic lesions using tomotherapy.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-11-24; most recent amendment 2025-02-12.
Status change: Recruiting → Active, Not Recruiting 2023-10-12
Status change: Not Yet Recruiting → Recruiting 2021-03-23
Trial Details
NCT Number NCT04643574
Lead Sponsor Centre Hospitalier Universitaire Vaudois
Conditions Solid Tumor, Adult
Enrollment 42 participants
Start Date 2021-03-09
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2025-02-14